SOLACEA-H in Heparin-sparing Haemodialysis

Inclusion Criteria: * On haemodialysis for at least 3 months * Dialysis in a haemodialysis department of the Ramsay-Santé group * No active infection * Medically stable * Blood flow ≥ 300 ml/min * Haemoglobin level stable and within recommended norms for a dialysis patient, id est \> 10g/dl * Bipunction * No known allergy to SOLACEA H or HYDROLINK-NVU * Willingness to comply with study procedures for the duration of the study * For women of childbearing age: effective contraception, or absence of active pregnancy (negative pregnancy test) * Member or beneficiary of a social security scheme * Patient having been informed and having signed an informed consent form Exclusion Criteria: * Patient on oral anticoagulants for the duration of the study * Patient on dialysate for the duration of the study * Patient Medically unstable or fragile * Severe hepatic impairment * Patient hospitalised without consent * Concurrent participation in another clinical study * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision * Pregnant, breast-feeding or parturient women * Patient unable to receive heparin * Known allergy to latex or phthalates